• Oluwatobi T Arisa, Erica L Beatson, Annieka Reno, Cindy H Chau, Rosemarie Aurigemma, Patricia S Steeg, and William D Figg.
• Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• Lancet Oncol. 2024 Dec 1; 25 (12): e685e693e685-e693.

AbstractThe translation of basic drug discoveries from laboratories to clinical use presents substantial challenges. Factors such as insufficient funding, misdirected project focus, and inability to understand a drug's limitations or strengths contribute to the difficulty of this process. To address these issues, the National Institutes of Health (NIH) has established various resources dedicated to streamlining drug development. The NIH offers access to regularly curated databases encompassing categories like drug discovery, target discovery, genomics, proteomics, and clinical datasets. The NIH also provides access to key resources through various programmes, such as the Developmental Therapeutics Program, focusing on preclinical drug discovery and the Cancer Therapy Evaluation Program, which oversees clinical trial efforts for investigational agents. These resources might include funding opportunities, access to a network of scientific experts, and services to address gaps in scientific work. This Review explores the diverse platforms and resources available at the NIH and outlines how researchers can leverage them to expedite the drug development process.Copyright © 2024 Elsevier Ltd. All rights reserved.

14 keywords...

hide…